文献速递妇科产科

局部晚期子宫内膜癌患者顺铂联合放疗后卡铂/紫杉醇对比卡铂/紫杉醇的患者报告结局:一项NRG肿瘤学研究

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
PubMed 文献 · Gynecol Oncol · 2021-12-11

在III期或IVA期子宫内膜癌患者中,顺铂联合放疗后卡铂/紫杉醇(Cis-RT+CP)对比单纯卡铂/紫杉醇(CP)未显示无复发生存优势。本研究描述治疗对生活质量、神经毒性和胃肠道症状量表心理测量学特性的影响至治疗后1年。

要点

  • 治疗结束时Cis-RT+CP组生活质量较CP组显著下降,但未达临床意义的最小重要差异。
  • 两组化疗诱导的神经毒性症状均增加,CP组评分更差且在化疗完成时达峰值。
  • Cis-RT+CP组放疗后胃肠道症状较CP组显著更差,但最小重要差异无意义。

核心结论

  • 患者报告结局表明,局部晚期子宫内膜癌化疗放疗组较单纯化疗组经历更差的健康相关生活质量和胃肠道毒性,但基于最小重要差异,这些差异无临床意义。
  • 胃肠道症状分量表是可靠有效的量表,对未来试验有价值。

研究设计与样本

  • 随机对照试验的生活质量子研究,比较Cis-RT+CP与CP在III期或IVA期子宫内膜癌患者中的患者报告结局。
  • 生活质量评估安排在基线、6周(Cis-RT+CP组完成放疗后或CP组第3周期前)、18周(治疗结束)和70周(治疗结束后1年)。

主要发现

  • 治疗结束时,Cis-RT+CP组报告的生活质量较CP组统计学显著下降,体现在身体健康、功能健康和子宫内膜癌特定关注方面,但最小重要差异未被视为临床意义。
  • 两组均报告化疗诱导的神经毒性症状增加,CP组评分更差,症状在化疗完成时达峰值。
  • Cis-RT+CP组放疗后胃肠道症状较CP组统计学显著更差,贯穿各评估间隔,但最小重要差异无意义。
  • 心理测量学评估表明胃肠道症状量表可靠、有效且对变化敏感。

关键数值与推荐

  • 生活质量工具包括FACT-En TOI、FACT/GOG-神经毒性(Ntx)分量表(简版)和胃肠道症状分量表。
  • Cis-RT+CP组治疗结束时生活质量较CP组统计学显著下降,但最小重要差异未达临床意义。
  • Cis-RT+CP组放疗后胃肠道症状较CP组统计学显著更差,但最小重要差异无意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein. METHODS: QOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT + CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale. RESULTS: At the end of treatment, patients receiving Cis-RT + CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT + CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change. CONCLUSIONS: PROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and valid scale that has value for future trials. TRIAL REGISTRATION: NCT00942357.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matulonis UA, Huang HQ, Filiaci VL, et al. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecol Oncol. 2021. PMID: 34903380. doi:10.1016/j.ygyno.2021.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。